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Aim: To study the relationship between the genotype and the phenotype in the patients with Hermansky — Pudlak syndrome (HPS) 
associated with granulomatous colitis; to monitor clinical course of the disease for adequate treatment, cancer surveillance and 
genetic counseling. Materials and Methods: The diagnosis of HPS is established by physical examination, chest X-ray, computed 
tomography, endoscopic examination with biopsy, and laboratory tests, including histology, baseline laboratory blood, urine and 
feces tests, determination of ASCA-C and ANCA antibodies using an ELISA. Molecular genetic testing for HPS gene mutations, 
R702W, G908R, L1007fs and P268S mutations in NOD2 gene, and TaqI variant of the VDR gene were carried out. Results: 
We report 2 cases of HPS from unrelated families. Both were complicated by inflammatory bowel disease with pathologic features 
of Crohn’s disease refractory to antibiotics and corticosteroids. One patient (family 1) with Ashkenazi Jewish ancestry had patho-
genic variant of the HPS-4 gene in exon 8, mutation P268S of NOD2 genes and “Tt” genotype of TaqI variant of the VDR gene. 
Another patient (family 2) carried two mutations P268S and G908R of NOD2 gene, and had a large paraovarian cyst diagnosed. 
No consistent success with the standard medical therapy, used for treating granulomatous colitis, associated with HPS, in presented 
cases was achieved. Patients needed surgical interventions at a young age and a long-term surveillance of the probable develop-
ment of tumors and other complications. Azathioprine at 2 mg/kg/day and mesalazine 3 g/day were used with some positive effect 
for prevention of Crohn’s disease postoperative recurrence. Conclusion: The occurrence of perianal lesions, the histopathological 
findings and the results of the molecular genetic analysis confirmed the mutations P268S and G908R of NOD2 gene in these cases 
suggest that HPS was truly associated with Crohn’s disease variant with early onset and severe course. The search for the molecular 
causes of the disease in some individuals may help in the development of new therapeutic and surgical approaches, as well in the 
improvement of understanding of premalignant inflammatory conditions in a large bowel.
Key Words: Hermansky — Pudlak syndrome, Crohn’s disease, HPS, NOD2 and VDR genes mutations, therapeutic treatment, 
surgical interventions, cancer surveillance.
Inflammatory bowel disease �IBD� is among t�e top 
t�ree �ig�-risk conditions for colorectal cancer� similar 
to familial adenomatous polyposis and �ereditary non-
polyposis colorectal cancer [�]. In case of early and 
severe onset of IBD in t�e c�ild�ood groups� t�e disease 
may be caused by mutations in genes responsible for 
severe monogenic disorders suc� as Hermansky — 
Pudlak syndrome �HPS� [�]. HPS is a rare autosomal 
recessive disorder consisting of a triad of manifestations 
of albinism� increased bleeding tendency secondary 
to platelet dysfunction� and systemic complications 
associated wit� accumulation of ceroid lipofusion [�� �]. 
T�e prevalence of t�e variant of HPS — HPS-� in nort�-
western Puerto Rico is �/����� population [5� 6]� but 
in non-Puerto Rican populations t�e prevalence of syn-
drome is estimated at ��9/��������� �www.orp�a.net�� 
but in Ukraine it is not known.
Originally described in �959 by Drs. Herman-
sky and Pudlak� HPS is now known to be a disease 
of lysosome-related organelles [�]. T�e disorder 
usually presents in early c�ild�ood� but may present 
at older ages� wit� tyrosinase-positive oculocutane-
ous albinism �varying degrees of �ypopigmentation�� 
reduced visual acuity �often at/below t�e level of legal 
blindness�� �orizontal nystagmus� easy bruising of soft 
tissues� epistaxis� prolonged bleeding after dental 
extraction� surgery or c�ildbirt�. Women may present 
wit� medically significant menstrual bleeding [�� 9]. 
Differential diagnoses include ot�er forms/causes 
of oculocutaneous albinism� i.e.� X-linked ocular 
albinism� C�ediak — Higas�i syndrome� Griscelli 
syndrome� Cross syndrome� pulmonary fibrosis and 
�emop�agocytic lymp�o�istiocytosis [��].
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HPS is c�aracterized by a storage pool deficiency 
of platelets and can be caused by mutations in one 
of several genes: HPS1 ���q��.��� AP3B1 �5q��.�; 
causing HPS-��� HPS3 ��q���� HPS4 ���q��.��q��.��� 
HPS5 ���p�5-p���� HPS6 ���q��.���� DTNBP1 �6p��.�; 
HPS-��� and BLOC1S3 ��9q��; HPS-��. T�e product 
of AP�B� codes for t�e beta �A subunit of adaptor 
complex-� �AP-��� involved in vesicle formation and 
protein sorting. T�e function of t�e ot�er HPS gene 
products is unknown� but t�ey interact wit� eac� 
ot�er in biogenesis of lysosome-related organelle 
complexes �BLOCs�; BLOC-�: HPS�� HPS5 and 
HPS6; BLOC-�: HPS� and HPS�. Targeted analysis 
for t�e HPS3 splice site variant c.��6�+�G>A can 
be performed first in individuals of As�kenazi Jewis� 
ancestry. HPS� and HPS� form a protein complex 
called BLOC-�. Affected lysosome-related organelles 
include melanosomes in melanocytes� delta granules 
in platelets� lamellar bodies in pulmonary type II cells� 
and secretory granules in T-cells. Of t�e eig�t geno-
typic subtypes �HPS-� to HPS-��� t�e first subtype 
�HPS-�� is t�e most common [��]. HPS types � and 
� are associated wit� gastrointestinal complica-
tions related to granulomatous colitis� enterocolitis� 
ileitis� intestinal fistulization or granulomatous peri-
anal disease t�at is pat�ologically and p�enotypi-
cally indistinguis�able from Cro�n’s disease [�����]. 
T�ese observations suggest t�at t�e colitis of HPS 
is due to t�e development of classical Cro�n’s dis-
ease. T�erefore� it is possible t�at treatments known 
to be effective for Cro�n’s disease would be effective 
for HPS-associated enterocolitis [�5]. Complications 
may include in HPS-� or HPS-�� pulmonary fibrosis 
also. Pulmonary fibrosis is t�e most serious complica-
tion and usually presents in t�e fourt� or fift� decade. 
HPS is associated wit� solar keratoses �premalignant 
lesions�� lung and skin cancer �basal cell carcinoma 
and squamous cell carcinoma� [�6� ��].
Cro�n’s disease is c�aracterized by c�anges 
in intestinal microbiota� focal translocation of bac-
teria across t�e mucosal barrier� altered mucosal 
response to bacterial invasion� development of c�ronic 
granulomatous inflammation. Genetic factors leading 
to a leaky epit�elial barrier and impaired mec�anisms 
of p�agocytosis and autop�agy. W�atever is t�e 
particular combination of factors in eac� patient� t�e 
common result is a granulomatous inflammation and 
activation of T cell immunity [��]. T�e innate immune 
receptor nucleotide oligomerization domain con-
taining � �NOD2� was t�e first gene associated wit� 
Cro�n’s disease [�9� ��]. T�ree mutations �R���W� 
G9��R and L����fs� in t�e NOD2 coding region were 
demonstrated to be associated wit� Cro�n’s disease 
in affected patients t�at carried at least one vari-
ant [��]. Genetic susceptibility to Cro�n’s disease 
s�ows significant et�nic differences. T�e mec�anisms 
linking NOD2 variants to t�e risk of Cro�n’s disease 
are not fully clear. Anot�er strong association wit� 
Cro�n’s disease regards t�e autop�agy related �6-
like � �ATG16L1� gene [��].
HPS to be very rare� but it is expected t�at in t�e 
severe form of early onset of IBD �EO-IBD� including 
Cro�n’s disease in t�e c�ild�ood groups� genetic fac-
tors play a significant role in pat�ogenesis. In EO-IBD 
t�e disease tend to be muc� more severe and muc� 
more difficult to control wit� conventional t�erapies� 
compared wit� adult-onset IBD. Increasing evidence 
suggest a stronger genetic contribution to t�ese forms 
compared wit� adults. Some patients wit� EO-IBD 
or very early onset �VEO-IBD� may �ave developed 
intestinal inflammation as a part of a monogenic dis-
ease� usually a primary immunodeficiency disease [�]. 
In fact� t�ese cases may account� at least in part� for 
t�e p�enomenon of missing �eritability in IBD� w�ic� 
is t�e inability to explain all t�e genetic contribution 
to IBD based solely on t�e additive effect of common 
risk gene variants [��]. Distinguis�ing monogenic 
forms among VEO-IBD is a crucial importance to allow 
t�e best treatment. T�e pat�ogenesis of inflammation 
in c�ronic granulomatous disease could also be attrib-
uted to a deficiency of autop�agy� leading to autoin-
flammatory response dominated by IL-� release [��].
In various immune-related diseases low serum vita-
min D levels �ave been reported pointing to an immu-
noregulatory role. Vitamin D and its receptor �VDR� are 
known to interact wit� different players of t�e immune 
�omeostasis by controlling cell proliferation� antigen 
receptor signaling� and intestinal barrier function. 
In European Caucasian patients� a significantly �ig�er 
frequency of t�e TaqI polymorp�ism �genotype “tt”� 
was reported in Cro�n’s disease compared to �ealt�y 
control individuals [�5]. T�is finding was replicated 
in German IBD patients w�ere t�e “tt” genotype was 
significantly more frequent in fistulizing and stenos-
ing Cro�n’s disease. VDR polymorp�isms �ave been 
identified in various diseases� suc� as cancer or cancer 
risk [�6].
T�e aim of t�is work is to study t�e relations�ip 
between t�e genotype and t�e p�enotype in t�e 
patients wit� HPS associated wit� granulomatous 
colitis; to monitor clinical course of t�e disease for 
adequate treatment� cancer surveillance and genetic 
counseling.
MATERIALS AND METHODS
We report t�e one patient wit� HPS from fam-
ily � �case �� and one patient wit� t�is syndrome from 
family � �case �� w�ic� were complicated by IBD. T�e 
diagnosis of HPS is establis�ed by p�ysical examina-
tion� c�est x-ray� �ig�-resolution computed tomog-
rap�y� endoscopic examination wit� biopsy samples 
from different part of t�e large bowel� baseline labora-
tory blood� urine and feces tests and molecular genetic 
analysis. Laboratory tests were performed for proper 
treatment: general and bioc�emical blood tests� cal-
protectin determination� anti-Saccharomyces cerevi-
siae antibodies �ASCA�� anti-neurotrop�ic cytoplasmic 
antibodies �ANCA-C�. Immunoglobulin G �IgG� ASCA 
and ANCA-C were measured by using an ELISA in se-
rum samples from patient �case ��. For t�e possibility 
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of tuberculosis of t�e intestine a tuberculin skin test 
was performed� w�ic� was negative.
Molecular genetic testing
T�is study was approved by t�e �ospital local et�-
ics committee and all t�e patients provided written 
informed consent. Blood samples were taken and DNA 
was extracted from t�e leukocytes of t�e perip�eral 
blood cells wit� t�e p�enol purification met�od [��].
Targeted analysis for t�e HPS-4 variant can be per-
formed in patient of As�kenazi Jewis� ancestry. �olecu-
lar genetic testing approac�es included serial single-
gene testing� using a multigene panel. Identification 
of biallelic pat�ogenic variant in HPS-4 confirms t�e 
diagnosis if clinical features are inconclusive. Targeted 
sequence analysis of HPS-4 for t�e patient was car-
ried out based on t�e severity of clinical findings� suc� 
as oculocutaneous albinism and granulomatous colitis. 
T�e identification of HPS gene mutation �case �� was 
carried out in t�e �edical Genetic Scientific Center 
��oscow� Russia�.
�olecular genetic testing for four mutations 
�R���W� G9��R� L����fs and P�6�S� in t�e NOD2 gene 
was carried out in t�e Institute of Human Genetics 
of t�e Polis� Academy of Sciences �Poznań� Poland�.
A polymerase c�ain reaction �PCR�-restriction frag-
ment lengt� polymorp�ism tec�nique was used to iden-
tify t�e mutations� w�ic� was confirmed by sequencing.
T�e variants of NOD2 gene associated wit� 
Cro�n’s disease are c.���� C>T �p.R���W�� 
c.����G>C �p.G9��R�� and ����insC �p.L����fs� 
localized in exons �� � and ��� corresponding to leucin 
ric� repeat protein domain or adjacent region [��� �9]. 
T�e exons �� �� �� of NOD2 gene were amplified using 
t�e following primers� designed by Primer� software:
Exon �F 5'AGTGCACAGCTTGTGAATGG�'�
Exon �R 5'GCTCCCACACTTAGCCTTGA�'�
Exon �F 5'CCACTCTGGGATTGAGTGGT�'�
Exon �R 5'TCCATTGCCTAACATTGTGG�'�
Exon ��F 5'GGACAGGTGGGCTTCAGTAG�'�
Exon ��R 5'CCTCAAAATTCTGCCATTCC�'.
Protocol was performed as previously described 
[��� ��]. For t�e amplification reaction was used 
a touc�down PCR protocol� consisting in � cycle 
of � min of denaturation at 9� °C� after w�ic� t�e DNA 
was amplified during �9 cycles� of w�ic� �� cycles 
consisted of �� s of denaturation at 9� °C� �� s of an-
nealing at 6� °C� decreasing �.5 °C eac� cycle� and 
�5 s of extension at �� °C; t�en �5 cycles of denaturation 
at 9� °C for �� s� �� s of annealing at 55 °C and �5 s of ex-
tension at �� °C. After amplification� t�e reaction mixture 
was subjected to a final cycle of � min of extension 
at �� °C. PCR products were subjected to sequence 
analysis performed on bot� strands wit� an automated 
procedure using t�e ���� Genetic Analyzer �Applied 
Biosystems�. PCR fragments were sequenced using 
t�e same primers used for PCR amplification.
�olecular genetic testing for variant TaqI of t�e 
VDR-� gene was carried out in t�e Institute of Hereditary 
Pat�ology of t�e National �edical Academy of Sciences 
�Lviv� Ukraine�. For t�e amplification reaction t�e PCR 
program mode �Saiki et al.� �9��� was used on t�e termo-
cyclers “A�PLY-�” �“Biokom”� �oscow� Russia�. Oligo-
nucleotide primers �ad been synt�esized in t�e Institute 
of Bioorganic C�emistry of t�e Russian Academy of Sci-
ences ��oscow� Russia�. Analysis of TaqI variant of t�e 
VDR-3 gene using �5 cycles of PCR wit� t�e following 
parameters were performed: 9� °C � min� 6� °C � min� 
�� °C � min. As a nucleators t�e following primers 
were used: 5'-CAGAGCATGGACAGGGAGCAA-�' and 
5'-GCAACTCCTCATGGCTGAGGTCTC-�'. T�e restric-
tases and t�e t�ermostable Taq-polymerase produced 
by t�e company “Fermentas” �Vilnius� Lit�uania�. T�e 
specificity of PCR products and t�e analysis of restrict 
fragments by means of electrop�oresis in � to �% aga-
rose gel were performed.
RESULTS AND DISCUSSION
Case 1. A �5-year-old girl of As�kenazi Jewis� an-
cestry wit� �allmark findings of HPS was admitted to t�e 
proctology department of t�e University Hospital com-
plaining of �-year �istory of recurrent episodes of ab-
dominal pain� general weakness� frequent defecations 
�6�� times/day� wit� intermittent blood and pain of t�e 
perineum area. P�ysical examination revealed an albino 
girl wit� w�itis� �air� pale and unpigmented skin and 
strabismus. Ocular examination s�owed �orizontal nys-
tagmus wit� reduced vision and no pigmentation of t�e 
iris. Cardiopulmonary examinations were normal. C�est 
x-ray and a �ig�-resolution computed tomograp�y 
didn’t s�ow any signs of pulmonary fibrosis. No signs 
of �emorr�agic diat�esis were observed at presenta-
tion. An ��-year-old brot�er of t�e proband also �as 
HPS. T�e pedigree of proband is s�own in Fig. �.
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Fig. 1. T�e pedigree of proband of As�kenazi Jewis� ancestry 
wit� HPS
Laboratory blood tests s�owed �ypoc�romic ane-
mia� leukopenia� and t�rombocytopenia. An increased 
level of calprotectin ���� ml/g� was observed� as well 
as �ig�er ASCA IgG ���.��6 units/ml� titers� and nor-
mal ANCA-C �5.�� units/ml� titers. T�e combination 
of a positive ASCA test wit� a negative ANCA-C test 
�as a positive predictive value of 96% and a specificity 
of 9�% for Cro�n’s disease [��]. ASCA+ patients �ave 
�ig�er frequency of mutant NOD2 alleles. Hig�er ASCA 
titers were associated wit� �ig�er probabilities stric-
turing/penetrating of Cro�n’s disease be�avior. T�is 
quantitative marker may prove useful in risk-stratifying 
patients to more aggressive anti-inflammatory t�era-
pies [��].
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Colonoscopy revealed bot� severe segmental 
colitis wit� numerous deep ulcers wit� sparing of t�e 
remainder of t�e colon� �emorr�ages in t�e submucosal 
layer� and stricture in sigmoid colon. T�is endoscopic 
appearance is �ig�ly reminiscent of Cro�n’s disease. 
Upper endo scopy s�owed erosive gastritis — t�e 
catarr�al bulbitis. Contrast en�anced computed to-
mograp�y of t�e abdomen s�owed t�ick-walled loops 
of sigmoid colon� wit�out evidence of perforation. His-
tologic findings of biopsy samples from t�e large bowel 
s�owed focal c�ronic inflammation� irregular villous 
arc�itecture� and granuloma formation wit� no obvious 
ceroid deposition. All t�e mucosal biopsies from t�e 
different colonic segments� included t�ose from ulcer 
bases� were negative for Mycobacterium tuberculosis.
T�e obtained laboratory results and �istologi-
cal examination corresponded to Cro�n’s disease 
of large bowel� associated wit� HPS� and c�aracter-
ized by early onset and severe c�ronic course. T�e 
patient was diagnosed wit� t�e c�ronic paraproctitis 
wit� rectovestibular and rectovaginal fistula. T�e 
patient underwent laparotomy and imposed a loop 
transverse colostomy of t�e left side in t�e rig�t side 
of t�e abdomen. Laparotomic wound closed primar-
ily. After applying a transverse colostomy t�e patient 
underwent an operation of perineum fistula incision 
by Gabriel met�od on t�e rectum. Despite t�e trans-
verse colostomy� t�e seams on t�e wound were parted 
and t�e wound of t�e perineum �ad been �ealing wit� 
a secondary tension. Before and after t�e operation 
t�e patient received suc� medications: etamsylate� 
ascorbinic acid wit� rutin� diosmectite� potassium and 
magnesium aspartate� and infusion t�erapy. Her con-
dition �as improved. However� after � mont�s� despite 
t�e treatment� rectovestibular fistulas relapsed. T�e 
patient received furt�er antibacterial t�erapy �cipro-
floxacin and metronidazole� for � weeks. According 
literature data fistulizing pattern in Cro�n’s disease 
is an independent risk factor for cancer [��]. T�e 
patient underwent a left-sided �emicolectomy �alf 
a year later at t�e Center of Coloproctology ��oscow� 
Russia�� because of t�e c�ronic perianal complica-
tions �Fig. ��.
Fig. 2. T�e preparation of removal large bowel wit� stricture� 
deep ulcers and �emorr�age in t�e submucosal layer
During t�e last two years� t�e patient several 
surgical interventions were performed regarding t�e 
persistently un�ealed perianal complications. Subse-
quently� a reconstructive operation of transverse-rec-
toanastomosis� ileostomy and drainage latex ligation 
t�roug� t�e fistulas on t�e perineum was performed. 
Postoperative wound �ealed badly. T�e patient re-
ceived specific t�erapy to prevent local complications 
in t�e perineum: azat�ioprine — 5� mg o.d.� metroni-
dazole-gel� 5-amynosalicillic acid suppositories. T�e 
patient is recommended to: �� continue azat�ioprine 
in t�e previous dose; �� start antibacterial t�erapy 
parenterally — ciprofloxacin and metronidazole for 
stopping purulent disc�arges; �� use 5-amynosalicillic 
acid suppositories wit� metronidazole gel; �� perform 
was�ing of fistulas wit� antiseptic solutions �dioxisol 
and betadine�; 5� anti-TNF-t�erapy wit� natalizumab 
or adalimumab.
T�e combination of t�e patient’s specific p�eno-
type wit� intestinal manifestation similar to Cro�n’s dis-
ease are likely to clinically assume a rare monogenic 
HPS� probably subtypes � or �� associated wit� 
c�ronic granulomatous colitis. Regarding t�e features 
of HPS-�� t�e collection of genealogical information 
was performed and molecular genetic studies were 
conducted. T�e parents of t�e proband are �ealt�y� 
but �er brot�er �as expressed signs of t�e HPS� w�ic� 
confirms t�e autosomal recessive type of in�eritance 
of t�e disease.
�olecular genetic analysis s�ows a marker muta-
tion� a pat�ogenic variant of t�e HPS-� gene in exon �. 
T�is mutation leads to a formation of t�e premature 
termination site of translation �c�r��: �6�6�5��G>A� 
in �c.6�9C>T� ��� codon �p.Arg���Ter�� confirming t�e 
subtype HPS-� �O�I� 6������� w�ic� is accompa-
nied by c�ronic granulomatous colitis� t�e most likely 
Cro�n’s disease. T�e attributed of HPS-4 pat�ogenic 
variant of gene among t�e in Non-Puerto Rican is 
~��.5%. Data based on approximately ��� individu-
als wit� HPS of non-Puerto Rican ancestry reported 
as of July ���� [�6]. No data on detection rate of gene-
targeted deletion/duplication analysis are available.
For proper treatment� t�e patient �ad been referred 
to additional molecular genetic studies: t�e identifica-
tion of t�e NOD2 gene mutations and t�e Taq� variant 
of t�e VDR gene� because patient �ad very low ion-
ized calcium level at �.�6 m�ol/l. T�e P�6�S variant 
of t�e NOD2 gene was confirmed to be �eterozygous. 
According to t�e literature data� t�is mutation is as-
sociated wit� Cro�n’s disease in some mostly small 
populations� suc� as As�kenazi Jews [�5]� represen-
tatives of some autonomous groups of C�ina� as well 
as Iranians and residents of Italy [�6� ��]. T�e t�ree 
NOD2 variants are associated wit� early onset and 
t�e presence of one variant allele increases t�e risk 
for developing Cro�n’s disease from �.5 to �.� folds� 
w�ile two allele variants increase susceptibility to de-
velop t�e disease from �� to �� folds compared wit� 
t�e general population [��]. In patient was confirmed 
“Tt” genotype of Taq� variant of t�e VDR gene t�at also 
pointed to t�e disturbance of calcium metabolism. T�e 
standard serum c�emistry examination s�ows lowered 
ionized calcium levels. Literature data �ig�lig�t t�e 
Experimental Oncology ��� ������ ���� ��arc�� ��
importance of vitamin D in different aspects of immune 
regulation� for example in c�ronic immune-mediated 
diseases and cancer. T�is suggests to considering 
t�e metabolite not simply as a vitamin involved in bone 
and calcium �omeostasis� but also an autocrine me-
diator wit� an active role in numerous p�ysiological 
processes� particularly in t�e innate immune system. 
Since most studies concerning t�e calcium status 
in IBD yielded contradictory data� t�e discussion �as 
focused in t�e most recent literature on t�e possible 
role of vitamin D as a risk factor for t�e onset and 
evolution of gut inflammation [�9].
Taking into account t�e stricture in t�e anal canal� 
functioning un�ealed fistulas� ineffectiveness of con-
servative t�erapy� t�e risk of malignancy� t�e patient 
an operation was proposed — extirpation of rectum� 
but t�e patient refused to undergo t�e intervention and 
continued conservative t�erapy.
Case 2. A �6-year-old female patient from t�e 
family �� �as HPS p�enotype: w�itis� �air� pale and 
unpigmented skin� �orizontal nystagmus� reduced 
visual acuity� granulomatous colitis� increased bleed-
ing tendency. Congenital ac�romatitis and psoriasis 
were also diagnosed. T�e first intestinal symptoms 
appeared at t�e age of �5 years. All t�e relatives of t�e 
proband are �ealt�y. T�e detection of mutations in t�e 
HPS gene was not carried out due to t�e �ig� cost 
of t�e analysis for t�e patient. T�e diagnosis of HPS 
was made clinically. At t�e age of �6 years� t�e pa-
tient �ad undergone surgical intervention — t�e total 
colproctectomy� because of severe total colitis. T�e 
ileoanal pouc� was formed� and t�e ileostoma was 
made. After �alf a year t�e ileostoma was closed. Post-
operative period was complicated by bleeding as a re-
sult of HPS-associated platelet disorder. T�e patient 
�ad extracolonic concomitant abdominal pat�ology: 
c�ronic pancreatitis and c�ronic nep�ritis. Currently� 
t�e patient is taking azat�ioprine at � mg/kg/day and 
mesalazine � g/day for prevention of postoperative 
recurrence of Cro�n’s disease. Despite t�e administra-
tion of adalimumab after intestinal resection surgery 
was greatly effective in preventing endoscopic and 
clinical recurrence of Cro�n’s disease [��]� but using 
t�is medication is less frequent in our patients due 
to t�e �ig� cost on it.
At t�e age of �� years t�e patient was diagnosed 
wit� a non-malignant neoplasm — a paraovarian 
cyst ��5 cm� near t�e rig�t ovary� caused compres-
sion on t�e intestinal pouc� and on t�e rig�t ureter� 
partial obstruction and first degree �ydronep�rosis. 
T�is urged a tubo-ovariectomy.
T�e patient was confirmed to carry two variants 
of t�e NOD2 gene: G9��R and P�6�S in a �etero-
zygous state. T�e “TT” genotype �wild type� of t�e 
Taq� variant of t�e VDR gene was detected in t�e 
patient.
No consistent success wit� t�e standard medi-
cal t�erapy was revealed in presented cases� except 
positive effect of azat�ioprine in one patient for treat-
ment of Cro�n’s disease� associated wit� HPS. T�ese 
patients need surgical intervention in young age. 
Insufficient information on pat�ogenesis� peculiarities 
of t�e course and treatment of c�ronic granulomatous 
colitis associated wit� HPS� makes eac� clinical case 
an important element in t�e accumulation of experi-
ence for surgeons� gastroenterologists� geneticists 
and �ematologists. EO- and VEO-IBD are often re-
sistant to routine treatment. T�erefore� t�e searc� for 
t�e molecular cause of t�e disease in some individuals 
may �elp in t�e development of new t�erapeutic and 
surgical approac�es to treatment. Accurate diagnosis 
of t�e HPS subtype �as important prognostic and 
treatment implications.
In cases of HPS-�� associated wit� c�ronic severe 
perianal complications� cramping� increased mu-
cus in t�e stool and rectal bleeding� patients s�ould 
be provided wit� information about preventing basal 
and squamous cell carcinoma. Hig�-risk patients �ave 
a need for ongoing regular follow-up� at least annual� 
and skin self-surveillance. For t�e patients at �ig� risk 
for neoplasia regular ultrasound surveillance is neces-
sary also. Patients wit� HPS need annual op�t�almo-
logic examination� at least annual examination of t�e 
skin for solar keratoses �premalignant lesions� [��]. 
In cases of HPS-�� associated wit� pulmonary fibro-
sis� annual pulmonary function testing is necessary 
in t�ose older t�an age �� years.
Patients wit� HPS in�erited in an autosomal reces-
sive manner need genetic counseling� considering bot� 
t�e risks of severe clinical course of Cro�n’s disease� 
it’s possible risk of transformation to cancer� and ma-
lignancy risks connected wit� albinism. Eac� siblings 
of proband �as a �5% c�ance of being affected� a 5�% 
c�ance of being an asymptomatic carrier� and a �5% 
c�ance of being unaffected and not a carrier. T�e prena-
tal diagnosis for pregnancies is possible for t�ose fami-
lies in w�ic� t�e pat�ogenic variants �ave been identified.
REFERENCES
1. Xie J, Itzkowitz S. Cancer in inflammatory bowel dis-
ease. World J Gastroenterol 2008; 14: 378–89.
2. Bianco AM, Girardelli M, Tommasini A. Genetics of in-
flammatory bowel disease from multifactorial to monogenic 
forms. World J Gastroenterol 2015; 21: 12296–310.
3. Erzin Y, Cosgun S, Dobrucali A, et al. Complicated 
granulomatous colitis in a patient with Hermansky — Pudlak 
syndrome, successfully treated with infliximab. Acta Gastro-
enterol Belg 2006; 69: 213–6.
4. Kouklakis G, Efremidou EI, Papageorgiou MS, et al. 
Complicated Crohn’s-like colitis, associated with Hermansky — 
Pudlak syndrome, treated with Infliximab: a case report and 
brief review of the literature. J Med Case Reports 2007; 1: 176.
5. Witkop CJ, Quevedo WC, Fitzpatrick TB, King RA. Al-
binism. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. 
The Metabolic and Molecular Basis of Inherited Disease. 6 ed. 
2. New York, NY: McGraw-Hill, 1989: 2905–47.
6. Witkop CJ, Nuñez Babcock M, Rao GH, et al. Albinism 
and Hermansky — Pudlak syndrome in Puerto Rico. Bol Asoc 
Med P R 1990; 82: 333–9.
7. Hermansky F, Pudlak P. Albinism associated with 
hemorrhagic diathesis and unusual pigmented reticular cells 
in the bone marrow: report of two cases with histochemical 
studies. Blood 1959; 14: 162–9.
�� Experimental Oncology ��� ������ ���� ��arc��
8. Hussain N, Quezado M, Huizing M, et al. Intestinal 
disease in Hermansky — Pudlak syndrome: Occurrence 
of colitis and relation to genotype. Clin Gastroenterol Hepatol 
2006; 4: 73–80.
9. Zach K, Misra L. Anesthetic management of a patient 
with Hermansky — Pudlak syndrome. Open J Anesthesiol 
2015; 5: 33–6.
10. Lewis RA. Ocular albinism, X-linked GeneRe-
views® [Internet]. November 19, 2015. Chédiak–Higashi 
syndrome. J Ghaffari, S Abdolrahim, RM Gharagozlou. 
J Pediatr Rev 2013; 1: 80–7.
11. Hurford MT, Sebastiano C. Hermansky — Pudlak 
syndrome: report of a case and review of the literature. Int 
J Clin Exp Pathol 2008; 1: 550–4.
12. Mora AJ, Wolfsohn DM. The management of gastro-
intestinal disease in Hermansky — Pudlak syndrome. J Clin 
Gastroenterol 2011; 45: 700–2.
13. Erzin Y, Cosgun S, Dobrucali A, et al. Complicated 
granulomatous colitis in a patient with Hermansky — Pudlak 
syndrome, successfully treated with infliximab. Acta Gastro-
enterol Belg 2006; 69: 213–6.
14. De Leusse A, Dupuy E, Huizing M, et al. Ileal 
Crohn’s disease in a woman with Hermansky — Pudlak syn-
drome. Gastroenterol Clin Biol 2006; 30: 621–4.
15. Hazzan D, Seward S, Stock H, et al. Crohn’s-like coli-
tis, enterocolitis and perianal disease in Hermansky — Pudlak 
syndrome. Colorectal Dis 2006; 8: 539–43.
16. Huizing MM, Malicdan CV, Gochuico BR, 
Gahl WA. Hermansky — Pudlak Syndrome GeneRe-
views® [Internet] Initial Posting: July 24, 2000; Last Up-
date: October 26, 2017.
17. Takanashi K, Ishida T, Ogura G, et al. Diagnostic 
usefulness of bronchoalveolar lavage in HPS: a case of duble 
lung cancer. Int Med 2004; 43: 972–6.
18. Tommasini A, Pirrone A, Palla G, et al. The universe 
of immune deficiencies in Crohn’s disease: a new viewpoint 
for an old disease? Scand J Gastroenterol 2010; 45: 1141–9.
19. Hugot JP, Chamaillard M, Zouali H, et al. Associa-
tion of NOD2 leucine-rich repeat variants with susceptibility 
to Crohn’s disease. Nature 2001; 411: 599–603.
20. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mu-
tation in NOD2 associated with susceptibility to Crohn’s dis-
ease. Nature 2001; 411: 603–6.
21. Vermeire S, Wild G, Kocher K, et al. CARD15 ge-
netic variation in a Quebec population: prevalence, genotype-
phenotype relationship, and haplotype structure. Am J Hum 
Genet 2002; 71: 74–83.
22. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide 
association study identifies new susceptibility loci for Crohn 
disease and implicates autophagy in disease pathogenesis. Nat 
Genet 2007; 39: 596–604.
23. Bianco AM, Zanin V, Girardelli M, et al. A common 
genetic background could explain early-onset Crohn’s disease. 
Med Hypotheses 2012; 78: 520–2.
24. de Luca A, Smeekens SP, Casagrande A, et al. IL-1 re-
ceptor blockade restores autophagy and reduces inflammation 
in chronic granulomatous disease in mice and in humans. Proc 
Natl Acad Sci USA 2014; 111: 3526–31.
25. Simmons JD, Mullighan C, Welsh KI, Jew-
ell DP. Vitamin D receptor gene polymorphism: association 
with Crohn’s disease susceptibility. Gut 2000; 47: 211–4.
26. Köstner K, Denzer N, Müller CSL, et al. The rel-
evance of vitamin D receptor (VDR) gene polymorphisms 
for cancer: a review of the literature. Anticancer Res 2009; 
29: 3511–36.
27. Lahiri DK, Schnabel B. DNA isolation by a rapid 
method from human blood samples: effects of MgCl2, EDTA, 
storage time, and temperature on DNA yield and quality. 
Biochem Genet 1993; 31: 321–8.
28. Vavassori P, Borgiani P, Biancone L, et al. CARD15 mu-
tation analysis in an Italian population: Leu1007fsinsC but 
neither Arg702Trp nor Gly908Arg mutations are associated 
with Crohn’s disease. Inflamm Bowel Dis 2004; 10: 116–21.
29. Giachino D, van Duist MM, Regazzoni S, et al. 
Analysis of the CARD15 variants R702W, G908R and L1007fs 
in Italian IBD patients. Eur J Hum Genet 2004; 12: 206–12.
30. Scudiero O, Monaco ML, Nigro E, et al. Mannos-
ebinding lectin genetic analysis: possible protective role of the 
HYPA haplotype in the development of recurrent urinary tract 
infections in men. Int J Infect Dis 2014; 19: 100–2.
31. Daniele A, Cammarata R, Pasanisi F, et al. Molecular 
analysis of the adiponectin gene in severely obese patients from 
southern Italy. Ann Nutr Metab 2008; 53: 155–61.
32. Quinton JF, Sendid B, Reumaux D, et al. Anti-
Saccharomyces cerevisiae mannan antibodies combined with 
antineutrophil cytoplasmic autoantibodies in inflammatory 
bowel disease: prevalence and diagnostic role. Gut 1998; 
42: 788–91.
33. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. An-
tibodies to saccharomyces cerevisiae in Crohn’s disease: higher 
titers are associated with a greater frequency of mutant NOD2/
CARD15 alleles and with a higher probability of complicated 
disease. Inflamm Bowel Dis 2007; 13: 143–51.
34. Biacone L, Zuzzi S, Ranieri M, et al. Fistulizing pat-
tern in Crohn’s disease and pancolitis in ulcerative colitis are 
independent risk factors for cancer: a single center cohort study. 
J Crohn’s Colitis 2012; 6: 578–87.
35. Sugimura K, Taylor KD, Lin YC, et al. A novel NOD2/
CARD15 haplotype conferring risk for Crohn disease in Ash-
kenazi Jews. Am J Hum Genet 2003; 72: 509–18.
36. Long WY, Chen L, Zhang CL, et al. Association be-
tween NOD2/CARD15 gene polymorphisms and Crohn’s dis-
ease in Chinese Zhuang patients. World J Gastroenterol 2014; 
20: 4737–44.
37. Scudiero O, Nigro E, Monaco ML, et al . 
C.802C>T NOD2/CARD15 SNP is associated to Crohn’s Dis-
ease in Italian patients. Hereditary Genetics 2015: S7.
38.  Lakatos PL, Lakatos L, Szalay F, et al. Toll-like recep-
tor 4 and NOD2/CARD15 mutations in Hungarian patients 
with Crohn’s disease: phenotype-genotype correlations. World 
J Gastroenterol 2005; 11: 1489–95.
39. Ardesia M, Ferlazzo G, Fries W. Vitamin D and 
inflammatory bowel disease. BioMed Res Int 2015; Article 
ID 470805, 16.
40. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab 
is more effective than azathioprine and mesalamine at prevent-
ing postoperative recurrence of Crohn’s disease: a randomized 
controlled trial. Am J Gastroenterol 2013; 108: 1731-42.
41. Kouklakis G, Efremidou EI, Papageorgiou MS. Com-
plicated Crohn’s-like colitis, associated with Hermansky — 
Pudlak syndrome, treated with Infliximab: a case report and 
brief review of the literature. J Med Case Reports 2007; 1: 176.
Copyright © Experimental Oncology, 2018
